We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

CT-2106 for the Second Line Treatment of Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00291837
Recruitment Status : Completed
First Posted : February 15, 2006
Last Update Posted : February 26, 2010
Information provided by:
CTI BioPharma

Brief Summary:
The purpose of this sudy is to determine the response rate of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: CT-2106 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen
Study Start Date : November 2004
Primary Completion Date : June 2006
Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer
U.S. FDA Resources

Primary Outcome Measures :
  1. response rate

Secondary Outcome Measures :
  1. toxicity
  2. response duration
  3. time to progression
  4. survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with advanced ovarian carcinoma, who have failed one prior platinum and taxane containing regimen
  • Only one prior chemotherapy containing either cisplatin or carboplatin plus taxanes administered concomitantly
  • At least one measurable lesion according to RECIST
  • ECOG performance status 0 or 1
  • at least 18 years old
  • Adequate haematological function
  • Adequate renal and hepatic functions
  • Normal coagulation parameters

Exclusion Criteria:

  • Platinum-sensitive patients (Group 2) who responded (CR or PR) to a 1st line therapy and subsequently progressed or relapsed after a treatment-free interval of > 12 months
  • Pregnant or lactating patients
  • Prior treatment with camptothecins
  • Presence or history of CNS metastasis or carcinomatous leptomeningitis;
  • Current active infection per investigator assessment;
  • Unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or ulcerative colitis;
  • Current history of chronic diarrhea >= grade 1 (CTCAE version 3);
  • Surgery or radiotherapy ≤ 4 weeks before first study treatment. In case of cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st study treatment are allowed;
  • Other uncontrolled, serious illness or medical condition, as determined by the investigator;
  • Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation;
  • Concurrent treatment with any other anti-cancer therapy;
  • Known HIV positivity or AIDS-related illness;
  • Patients who cannot be regularly followed up for psychological, social, familial or geographic reasons.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00291837

Lyon, France
Saint Brieuc, France
Campobasso, Italy
United Kingdom
Birmingham, United Kingdom
London, United Kingdom
Newcastle upon Tyne, United Kingdom
Surrey, United Kingdom
Sponsors and Collaborators
CTI BioPharma
Principal Investigator: Hilary Calvert, PhD Newcastle General Hospital

ClinicalTrials.gov Identifier: NCT00291837     History of Changes
Other Study ID Numbers: CAM203
First Posted: February 15, 2006    Key Record Dates
Last Update Posted: February 26, 2010
Last Verified: February 2010

Keywords provided by CTI BioPharma:

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action